SHBG ELISA
- Known as:
- SHBG Enzyme-linked immunosorbent assay test
- Catalog number:
- kapd2996
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Diasource
- Gene target:
- SHBG ELISA
Related genes to: SHBG ELISA
- Gene:
- SHBG NIH gene
- Name:
- sex hormone binding globulin
- Previous symbol:
- -
- Synonyms:
- ABP, TEBG, MGC126834, MGC138391
- Chromosome:
- 17p13.1
- Locus Type:
- gene with protein product
- Date approved:
- 1990-03-14
- Date modifiied:
- 2016-04-04
Related products to: SHBG ELISA
Related articles to: SHBG ELISA
- Polycystic ovary syndrome (PCOS) is a lifelong endocrine‑metabolic disorder affecting 11‑13% of women worldwide. Beyond ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology, PCOS is tightly linked to insulin resistance, dyslipidemia, hypertension, and increased cardiometabolic risk. Converging evidence places oxidative stress at the core of PCOS pathophysiology, but current evidence should be interpreted in a phenotype‑aware manner. Obese, hyperandrogenic, and Rotterdam phenotype A/B presentations generally carry a heavier systemic oxidant‑inflammatory burden than phenotype D, whereas lean PCOS may still exhibit clinically relevant local ovarian redox abnormalities despite a milder metabolic background. Mitochondrial dysfunction, insulin resistance, and androgen excess amplify reactive oxygen species generation, while granulosa‑cell mitochondrial depolarization, apoptotic signaling, and NF‑κB‑driven inflammation degrade follicular fluid quality, oocyte competence, and embryo development. However, the literature remains heterogeneous because assay platform, specimen type, cycle phase, adiposity, and treatment exposure all influence biomarker reproducibility and comparability. In addition, most human research supports association, whereas stronger causal support comes from interventional or mechanistic research showing that modulation of NADPH oxidase 4, antioxidant pathways, mitochondrial function, or sex hormone‑binding globulin‑related oxidative signaling can alter key reproductive and metabolic phenotypes. To improve translational value, the present review prioritizes a core biomarker panel spanning serum/plasma and follicular fluid, distinguishes systemic oxidative markers from local ovarian microenvironmental markers, and critically compares antioxidant and metabolic interventions by evidence level, sample size, endpoint type, and major limitations. Recent phenotype‑oriented and multi‑omics reearch is further integrated to propose a biomarker‑guided framework for phenotype‑stratified trials and precision management of PCOS. - Source: PubMed
Publication date: 2026/08/21
Qiu YuenaGuo XiaojingAn Jie - A man in his 50s with long-standing learning difficulties and schizophrenia currently treated with clozapine presented with gynaecomastia and a new right testicular mass. He was noted to have a severe tremor interfering with activities of daily living treated with combination levodopa + benserazide, primidone and topiramate. Investigations revealed elevated prolactin, gonadotropins, sex hormone binding globulin, total testosterone and oestradiol. Right orchidectomy revealed Leydig cell hyperplasia. Karyotyping diagnosed Klinefelter syndrome. Testosterone replacement therapy (TRT) was commenced, with subsequent marked improvement in his debilitating tremor. Tremor is a potentially disabling complication of Klinefelter syndrome with fewer than 50 cases reported in the literature. The pathophysiology of tremor in Klinefelter syndrome is unclear. Tremor in Klinefelter syndrome is often refractory to anti-tremor medical therapy; however, as reported in this case, testosterone therapy may improve tremor in Klinefelter syndrome. It is rare for TRT to significantly improve tremor as reported in this case. - Source: PubMed
Publication date: 2026/08/20
Houssarini JaredHsieh AlbertHocking Samantha - Glucagon-like peptide receptors-1 agonists (GLP-1 agonists) have revolutionized the treatment of obesity and diabetes due to their potent effects on weight and glycemic control, and cardiorenal protection. However, emerging reports and post-marketing surveillance have raised concerns regarding erectile dysfunction (ED) or impotence in a subset of male patients. - Source: PubMed
Publication date: 2026/09/20
Mirghani Hyder OsmanAlQurashi Asawir Mohammed - Sex-based differences in trauma outcomes are well documented, but the early molecular programs distinguishing male and female responses remain incompletely defined. We hypothesized that biological sex shapes the circulating proteomic and metabolomic response at emergency department arrival and that these signatures interact with age, injury severity, and shock physiology. - Source: PubMed
Publication date: 2026/08/21
Baig Huma SErickson ChristopherSen SanchayitaRamser BenjaminStocker BenjaminSublette ChristopherBorg TeressaMokhtari AvaSamuel RachelCardenas JessicaHansen KirkD'Alessandro AngeloCohen Mitchell - Osteoporosis is a major health issue that has implications worldwide, both clinically and socioeconomically. Therefore, searching for informative bone health biomarkers that provide early information on bone changes and assess treatment efficacy is essential. Previously, our group used label-free proteomics and bioinformatic approaches to analyze the serum proteomic profile of postmenopausal women with normal bone mineral density (BMD), osteopenia, and osteoporosis. Based on their role in bone metabolism and literature review, a panel of 12 candidate serum biomarkers for low BMD was proposed. - Source: PubMed
Publication date: 2026/08/05
Aparicio-Bautista Diana IBecerra-Cervera AdrianaRivera-Paredez BereniceJiménez-Ortega Rogelio FLópez-Pérez Tania VSalmerón JorgeReyes-Grajeda J PabloHidalgo-Bravo AlbertoVelázquez-Cruz Rafael